- Home
- PRQR vs CCCC Comparison
PRQR vs CCCC Comparison
Compare PRQR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRQR | CCCC |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.3M | 177.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PRQR | CCCC |
|---|---|---|
| Price | $1.45 | $1.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $7.67 | $7.25 |
| AVG Volume (30 Days) | 408.8K | ★ 1.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.44 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.07 | $1.09 |
| 52 Week High | $3.10 | $3.65 |
Technical Indicators
Market Signals| Indicator | PRQR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 41.78 |
| Support Level | $1.33 | $1.74 |
| Resistance Level | $1.54 | $1.97 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 31.94 | 29.98 |
Price Performance
Historical ComparisonAbout PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.